Shingles vaccine

Vista sencilla de ítem
dc.contributor.authorBeau Willison, C.
dc.contributor.authorMorrison, L. Katie
dc.contributor.authorMendoza, Natalia
dc.contributor.authorTyring, Stephen K.
dc.date.accessioned2021-02-19T15:19:22Z
dc.date.available2021-02-19T15:19:22Z
dc.date.issued2010
dc.description.abstractenglishImportance of the field: Herpes zoster or shingles is a condition with the potential to result in severe debilitation. It affects approximately 10 – 30% of the population. Until recently there were only treatments to shorten the duration and lessen the symptoms of herpes zoster, but no practical or approved method of prevention for susceptible immunocompetent adults. The live attenuated zoster vaccine (Zostavax®, Merck & Co., Inc.) is effective in preventing shingles in individuals 60 years of age and older and recommended by the Center for Disease Control's (CDC) Advisory Committee for Immunization Practices (ACIP). Areas covered in this review: Literature related to the live attenuated zoster vaccine is reviewed from its beginnings in the early 1970s through to the present. What the reader will gain: Background information on herpes zoster and up to date information on the live attenuated zoster vaccine including pharmacology, efficacy and safety are covered. New areas of research in zoster vaccination are also discussed. Take home message: The live attenuated zoster vaccine is an effective and well-tolerated method of preventing zoster and the potentially debilitating sequelae and is recommended for immunocompetent patients 60 years of age and older. Ongoing clinical trials are investigating new means of effective prevention.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1517/14712591003623203
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1744-7682
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/5390
dc.language.isoeng
dc.publisherTaylor & Francisspa
dc.publisher.journalExpert Opinion on Biological Therapyspa
dc.relation.ispartofseriesExpert Opinion on Biological Therapy, 1744-7682, Vol. 10, No. 4, 2010, p. 631-638spa
dc.relation.urihttps://www.tandfonline.com/doi/full/10.1517/14712591003623203
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2010-04
dc.rights.localAcceso abiertospa
dc.subject.keywordsAcute zosterspa
dc.subject.keywordsCell-mediated immunityspa
dc.subject.keywordsChickenpoxspa
dc.subject.keywordsHerpes zosterspa
dc.subject.keywordsOka/Merck VZVspa
dc.subject.keywordsPHNspa
dc.subject.keywordsPostherpetic neuralgiaspa
dc.subject.keywordsShinglesspa
dc.subject.keywordsVaccinationspa
dc.subject.keywordsVaccinespa
dc.subject.keywordsVaricella zoster virusspa
dc.subject.keywordsVarivaxspa
dc.subject.keywordsZostavaxspa
dc.titleShingles vaccinespa
dc.title.translatedShingles vaccinespa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Colecciones

Artículos